Cartesian Therapeutics Inc. Cash Flow Reinvestment Rate
Cartesian Therapeutics Inc. cash flow reinvestment rate. Cartesian Therapeutics Inc. (RNAC) has a Cash Flow Reinvestment Rate of 0.91x as of September 2024, reinvesting $12.40 Million (capex $6.20 Million plus investments $-6.20 Million) from operating cash flow of $13.69 Million. Explore Cartesian Therapeutics Inc. cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Cartesian Therapeutics Inc. (2020–2020)
Cash flow reinvestment rate of Cartesian Therapeutics Inc. from 2020 to 2020. Historical reinvestment intensity for Cartesian Therapeutics Inc. across 1 annual periods. Explore reinvestment intensity of Cartesian Therapeutics Inc. to see what proportion of operating cash flow is directed to capital expenditures.
Cartesian Therapeutics Inc. Cash Flow Reinvestment Rate by Year (2020–2020)
Cartesian Therapeutics Inc. cash flow reinvestment rate by year from 2020 to 2020. Year-by-year capital reinvestment analysis for Cartesian Therapeutics Inc.. For the full cash flow conversion analysis, see RNAC operating cash flow.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2020 | 0.04x | $1.56 Million | $34.88 Million | $815.00K | — |